GLPwatch
Mazdutide
Pipeline · GLP-1 and glucagon receptor dual agonist
Last updated 2026-07-12Mazdutide is an experimental drug that works by activating both the GLP-1 and glucagon receptors, which are involved in regulating blood sugar and appetite. It is being developed as a potential treatment for metabolic conditions, including obesity and type 2 diabetes, but has not yet been approved for any use.
AI summary of the sources below.
| Mechanism | GLP-1 and glucagon receptor dual agonist Acts on the GLP-1 and glucagon receptors, which affect blood sugar, appetite, and how the body uses energy. |
|---|---|
| Status | Pipeline |
| Branded products | — (none approved) |
| Manufacturer(s) | eli-lilly |
How Mazdutide connects
Trials (6)
- Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
- Efficacy of Mazdutide for Treating PCOS
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
- A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
- ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
- Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
Top research (22)
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
- Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.
- Mazdutide versus placebo in Chinese adults with type 2 diabetes.
- Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
- Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
- Mazdutide: First Approval.
- Once-Weekly Mazdutide in Obesity or Overweight. Reply.
- Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.
- Once-Weekly Mazdutide in Obesity or Overweight.
- Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.
- Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
- Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial.
- Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.
- Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.